ZR-75-30 Xenograft Model Service for Breast Cancer

The ZR-75-30 xenograft model provides a powerful, clinically relevant in vivo translational platform specifically optimized for validating candidate novel HER2-targeted therapies, ADCs, and cross-talk mechanisms between steroid receptors and growth factor pathways in breast cancer. Alfa Cytology delivers a comprehensive, end-to-end ZR-75-30 xenograft model service, combining fully authenticated cell line assets with standardized operational workflows and molecular profiling to accelerate preclinical oncology drug discovery pipelines.

Overview of ZR-75-30 Xenograft Model for Breast Cancer

The ZR-75-30 cell line is a highly specialized and molecularly complex human mammary carcinoma platform extensively utilized in preclinical oncology to study the biology of HER2-amplified, hormone-receptor-positive breast cancers. Originally derived from the malignant ascitic fluid of a 47-year-old Caucasian female patient undergoing therapy for an infiltrating ductal carcinoma, this model is characteristically categorized within the luminal B or HER2-overexpressing molecular subtype. Phenotypically, ZR-75-30 demonstrates a massive amplification of the ERBB2 (HER2) gene alongside a distinct, dual expression of functional ER and PR. This concurrent activation of the driving HER2 oncogenic pathway and steroid receptor axes makes ZR-75-30 an indispensable test matrix for deciphering target-mediated signaling cross-talk, tracking therapeutic escape networks, and testing dual-targeted combination regimens (such as combining anti-HER2 agents with selective estrogen receptor degraders).

When established in vivo as a xenograft in immunocompromised mice, ZR-75-30 cells develop into solid, moderately differentiated epithelial tumors that accurately replicate the aggressive growth profile, high proliferative index, and hyper-activated downstream PI3K/Akt and MAPK cascades observed in clinical patient populations.

Cell Line Information: ZR-75-30

The ZR-75-30 cell line maintains a stable epithelial morphology in vitro and reliably preserves its primary HER2 amplification, ER+/PR+ status, and specific drug sensitivity signatures upon in vivo transplantation.

Our Services

Alfa Cytology provides a fully integrated, turnkey solution for the ZR-75-30 Xenograft Model Service. Our dedication to quality begins with rigorous cell line authentication and mycoplasma testing. We manage every critical step of the preclinical journey—from standardized cell preparation, orthotopic or subcutaneous inoculation, in-life monitoring, to comprehensive endpoint analyses including IHC for HER2, ER, and PR status and PK/PD profiling. Leveraging our expertise in HER2-amplified, hormone-receptor-positive breast cancer models, we deliver robust data packages tailored to accelerate your drug discovery programs.

Workflow of ZR-75-30 Xenograft Model Construction

Alfa Cytology executes a standardized and strictly regulated workflow to build and validate the ZR-75-30 xenograft model:

• Cell Culture & Quality Control: ZR-75-30 cells are cultivated in cell-bank-certified growth media under optimized environmental parameters. Quality control verification involves mandatory STR profiling and mycoplasma clearance checks to guarantee phenotypic identity and purity before inoculation.
• Host Selection & Acclimatization: Standardized immunocompromised mice (such as BALB/c Nude or NOD/SCID strains) are selected based on specific study designs and acclimated to controlled facility parameters to ensure baseline physiological stability.
• Precision Inoculation: A calibrated suspension of high-viability ZR-75-30 cells is prepared and blended with a verified biological matrix carrier to optimize spatial cell distribution and support initial engraftment. The mixture is precisely injected in vivo via subcutaneous or orthotopic routes.
• Longitudinal Growth Tracking: Following model establishment, tumor growth kinetics are tracked systematically using high-precision digital calipers under continuous health monitoring. Animal weights and general welfare behavior are routinely recorded to establish dependable growth kinetics.
• Stratification & Dosing: Once the tumors reach a predetermined, statistically optimal volume range, animals are randomized into therapeutic cohorts to balance group parameters perfectly before dosing protocols begin.

Fig 1. ZR-75-30 Xenograft Model Construction Workflow

Case Study - ZR-75-30 Xenograft Model Development

In a recent preclinical trial conducted at Alfa Cytology, the ZR-75-30 xenograft model was successfully utilized to evaluate the efficacy of a novel next-generation antibody-drug conjugate (ADC) targeting HER2, both as a monotherapy and in combination with an oral endocrine agent. Under optimized modeling conditions and standardized matrix-assisted inoculation protocols, our technical team achieved highly reproducible tumor engraftment and exceptionally uniform growth curves across all experimental arms, allowing for an unobstructed assessment of therapeutic synergy.

Our Advantages

Choosing the right partner for your HER2-amplified, hormone-receptor-positive breast cancer research is critical for generating high-quality, reproducible data. Alfa Cytology stands out by offering specialized expertise and high-standard preclinical services:

• Model Authenticity: Fully verified human tumor cell lines with stable, traceable genetic hallmarks and confirmed high HER2 expression alongside ER+/PR+ co-expression.
• Technical Consistency: Optimized inoculation protocols utilizing customized matrix support to ensure uniform tumor growth and minimize variance across study cohorts.
• Multi-Parametric Endpoints: Capacity for advanced readouts, including digital tumor kinetics, target receptor density profiling, and PK/PD tissue processing.
• Regulatory Compliance: Studies executed by a specialized team adhering strictly to international preclinical research and animal welfare standards.

Contact Us

Are you looking to advance your therapeutic pipeline against aggressive, HER2-amplified breast cancer or evaluate novel dual-targeting regimens using the robust ZR-75-30 xenograft platform? The expert scientific team at Alfa Cytology is ready to build a customized study design that fulfills your strategic research goals. Please contact us today to speak directly with an oncology specialist and request a project-specific consultation and quotation.

For research use only. Not intended for any clinical use.